Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN3A | Q9NY46 | 2/20 | 0.38 |
| ▸ | NR1D1 | P20393 | 1/20 | 0.36 |
| ▸ | ITGA4 | P13612 | 2/20 | 0.35 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.35 |
| ▸ | MMP2 | P08253 | 1/20 | 0.35 |
| ▸ | ANPEP | P15144 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.34 |
| ▸ | CHRNA5 | P30532 | 1/20 | 0.34 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.34 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.34 |
| ▸ | CASP3 | P42574 | 1/20 | 0.34 |
| ▸ | CASP7 | P55210 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3947198 | 0.87 | NR1H2 (0.41) | CASP3 | |
| SCHEMBL18426092 | 0.82 | MMP2 (0.33) | MMP2ANPEP | |
| SCHEMBL13661938 | 0.81 | SCN3A (0.34) | SCN3AFFAR4ALDH1A1CASP3CASP7 | |
| SCHEMBL3249508 | 0.80 | MMP2 (0.35) | MMP2ANPEP | |
| SCHEMBL6974057 | 0.80 | NR1D1 (0.41) | NR1D1FFAR4 | |
| SCHEMBL26086744 | 0.80 | MMP2 (0.35) | MMP2ANPEP | |
| SCHEMBL3945694 | 0.80 | NR1D1 (0.41) | NR1D1FFAR4 | |
| SCHEMBL3945766 | 0.80 | MMP2 (0.35) | MMP2ANPEP | |
| SCHEMBL20484877 | 0.79 | SMYD2 (0.34) | MMP2ANPEP | |
| SCHEMBL1462582 | 0.79 | SMYD2 (0.34) | MMP2ANPEP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090264431-A1 | NOVEL CATHEPSIN C INHIBITORS AND THEIR USE | GLAXO GROUP LIMITED (GB) | 2009-10-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090264431-A1 | NOVEL CATHEPSIN C INHIBITORS AND THEIR USE | CTSB, CTSS, CTSF | SCN3A 2150/4885NR1D1 1663/4885ITGA4 3897/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.